{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:21:14Z","timestamp":1783405274773,"version":"3.54.6"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aromatase inhibitors have been successfully employed in clinical practice for the treatment of breast cancer (BC); however, the accompanying tendon disorders has often been underestimated. This study aimed to conduct a comprehensive empirical investigation and assess tendon disorders associated with third-generation aromatase inhibitors using data from the FDA\u2019s FAERS database. The goal was to provide a theoretical foundation for the rational application of these drugs in clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reports of tendon disorders related to third-generation aromatase inhibitors were retrieved from the FAERS database, covering the period from the first quarter of 2004 to the first quarter of 2024. The data were further analyzed using proportional analysis and a Bayesian approach to detect signals of tendon disorders induced by the three drugs. Additionally, the clinical characteristics, onset time, correlation, and stratification analysis of tendon disorders associated with the three drugs were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Positive signals for tendon disorders associated with third-generation aromatase inhibitors were identified. At the preferred term (PT) level, twelve positive signals were detected, with trigger finger and tenosynovitis stenosans presenting a significant signal. In terms of onset time, letrozole exhibited the earliest onset at 74 days, whereas exemestane showed the latest onset at 243.5 days. After excluding the effect of combination drugs, a clear association between third-generation aromatase inhibitors and tendon disorders was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Analysis of the FAERS database has identified risk trends for tendon disorders associated with third-generation aromatase inhibitors. Furthermore, the study reveals varying degrees of tendon toxicity related to these inhibitors, including distinct time-to-onset profiles and drug-specific signal intensities, providing valuable insights into associated tendon disorders in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1825180","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:47:56Z","timestamp":1783403276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuai","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Nanyang Central Hospital","place":["Nanyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Yao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Li","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-12-66","article-title":"The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model","volume":"12","author":"Arumugam","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: A review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000062","article-title":"Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant","volume":"1","author":"K\u00fcmler","year":"2016","journal-title":"ESMO Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12672-017-0314-5","article-title":"Harnessing a different dependency: How to identify and target androgen receptor-positive versus quadruple-negative breast cancer","volume":"9","author":"Christenson","year":"2018","journal-title":"Horm Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0093-7754(03)00302-6","article-title":"Aromatase inhibitors: Mechanism of action and role in the treatment of breast cancer","volume":"30","author":"Miller","year":"2003","journal-title":"Semin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05086-8","article-title":"Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors","volume":"174","author":"Xu","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2081","article-title":"Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development","volume":"121","author":"Shulman","year":"2008","journal-title":"Pediatrics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414827","article-title":"Letrozole, gonadotropin, or clomiphene for unexplained infertility","volume":"373","author":"Diamond","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.08.010","article-title":"Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer","volume":"102","author":"Ahmad","year":"2015","journal-title":"Eur J Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1185\/030079906x120940","article-title":"Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer","volume":"22","author":"Buzdar","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.3390\/ijms21165625","article-title":"Aromatase inhibitors-induced musculoskeletal disorders: Current knowledge on clinical and molecular aspects","volume":"21","author":"Tenti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1053458","article-title":"Safety of aromatase inhibitor therapy in breast cancer","volume":"14","author":"Lintermans","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt037","article-title":"Aromatase inhibitor-induced arthralgia: A review","volume":"24","author":"Niravath","year":"2013","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0192623317711614","article-title":"Mini-review: toxic tendinopathy","volume":"45","author":"Bolon","year":"2017","journal-title":"Toxicol Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/bcr2818","article-title":"Aromatase inhibitor-associated bone and musculoskeletal effects: New evidence defining etiology and strategies for management","volume":"13","author":"Gaillard","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.03.022","article-title":"Drug-induced tendinopathy: From physiology to clinical applications","volume":"81","author":"Kirchgesner","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: Signals from disproportionality analysis of the FDA adverse event reporting system","volume":"23","author":"Raschi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database","volume":"154","author":"Chen","year":"2024","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000505376","article-title":"Fractures due to aromatase inhibitor therapy for breast cancer: A real-world analysis of FAERS data in the past 15 years","volume":"43","author":"Song","year":"2020","journal-title":"Oncol Res Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: Data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000477956","article-title":"Extended adjuvant endocrine therapy in hormone receptor-positive early breast cancer","volume":"12","author":"Bracken-Clarke","year":"2017","journal-title":"Breast Care (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2174\/1389557517666171101100902","article-title":"Aromatase inhibitors evolution as potential class of drugs in the treatment of postmenopausal breast cancer women","volume":"18","author":"Avvaru","year":"2018","journal-title":"Mini-Rev Med Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients-a systematic review and meta-analysis","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.2174\/1871520620666200627204105","article-title":"Aromatase inhibitors for the treatment of breast cancer: A journey from the scratch","volume":"20","author":"Ratre","year":"2020","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000015052","article-title":"Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature","volume":"98","author":"Tenti","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem213","article-title":"Severe disabling tendinopathy caused by anastrazole","volume":"46","author":"Martens","year":"2007","journal-title":"Rheumatol (Oxford)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000491874","article-title":"Aromatase inhibitor-associated tendinopathy and muscle tendon rupture: Report of three cases of this exceedingly rare adverse event","volume":"11","author":"Mitsimponas","year":"2018","journal-title":"Case Rep Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902953738","article-title":"Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer","volume":"10","author":"Nabholtz","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0015","article-title":"Aromatase inhibitors in the treatment of breast cancer","volume":"26","author":"Brueggemeier","year":"2005","journal-title":"Endocr Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1517\/14740338.2010.515977","article-title":"Anastrozole","volume":"9","author":"Kelly","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28255","article-title":"LANA regulates miR-155\/GATA3 signaling axis by enhancing c-Jun\/c-Fos interaction to promote the proliferation and migration of KSHV-infected cells","volume":"95","author":"Luo","year":"2023","journal-title":"J Med Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/sms.13281","article-title":"Drug treatments associated with Achilles tendon rupture. A case-control study involving 1118 Achilles tendon ruptures","volume":"28","author":"Nyyss\u00f6nen","year":"2018","journal-title":"Scand J Med Sci Sports"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-33943-6_22","article-title":"Drug-induced tendon disorders","volume":"920","author":"Knobloch","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000003667","article-title":"Bleeding and antiplatelet therapies: A combined pharmacovigilance analysis of the FDA adverse event reporting system and Japanese adverse drug event report databases, and the role of pharmacists","volume":"112","author":"Li","year":"2026","journal-title":"Int J Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1594585","article-title":"Adverse events of pexidartinib for the treatment of TGCT: A real-world disproportionality analysis using FDA adverse event reporting system database","volume":"15","author":"Lin","year":"2025","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500x.120955","article-title":"Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two \"challenging\" case reports","volume":"4","author":"Palleria","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2019.08.007","article-title":"Adverse drug reactions","volume":"154","author":"Montan\u00e9","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070369","article-title":"Bias: Considerations for research practice","volume":"65","author":"Gerhard","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:47:57Z","timestamp":1783403277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":46,"alternative-id":["10.3389\/fonc.2026.1825180"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1825180","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1825180"}}